Axatilimab-csfr in Chronic Graft-Versus-Host Disease (cGVHD) - A Comprehensive Review

Overview

Axatilimab-csfr is an early investigational immunotherapy designed as a monoclonal antibody aimed at inactivating the colony-stimulating factor-1 receptor (CSF1R). This receptor is necessary for maintaining and differentiating macrophages involved in cGVHD. cGVHD is characterized by the infiltration of donor immune cells into the recipient’s tissues and the subsequent development of fibrosis and inflammation in the organ.

Axatilimab, by blocking CSF1R, minimizes this immune response because the tissue-resident macrophages that cause fibrosis and inflammation are reduced.

The condition performs best in patients who had unsatisfactory responses to conventional treatments like corticosteroids or other immunosuppressive drugs. Targeting CSF1R affects those immune cells, allowing them to return tissues to normal states and release patients from inflammation and fibrosis, such as joint stiffness, skin tightness, and organ dysfunction, frequently observed in cGVHD. The FDA(Food and Drug Administration)has provided breakthrough therapy status to Axatilimab, which can meet this need in the population of patients with cGVHD responding poorly to steroids. This approach is novel in providing a new option for treating cGVHD, improving the lives of patients affected by this difficult disease.

How Does Axatilimab-csfr Work?

Axatilimab-csfr works through the interaction with the anti-oncogene protein product CSF1R, which is present on the surface of macrophages and other immune cells. This interaction inhibits the receptor's signaling routes, which play an important role in macrophage proliferation, differentiation, and survival. Among these, macrophages represent a prominent cell population in the inflammatory context of cGVHD since they release fibrogenic and pro-inflammatory factors contributing to lesional fibrosis and inflammation.

By inhibiting CSF1R, Axatilimab reduces the number and activity of macrophages in affected tissues. This decreases fibrotic processes and inflammatory responses, promoting tissue repair and symptomatic relief. The mechanism of action makes Axatilimab-csfr an effective agent against chronic inflammatory conditions where traditional immunosuppressants may fail. It also has a more targeted approach, reducing the likelihood of broad immunosuppression and associated adverse effects, making it a promising option for the long-term management of cGVHD.

What Are the Indication of Axatilimab-csfr?

• Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD): Axatilimab is mainly used for cGVHD patients with suboptimal response to corticosteroids and standard therapies. This inflammatory disease results in chronic and progressive fibrosis of the skin, liver, lungs, and other vital organs, significantly reducing quality of life.

• Refractory Cutaneous and Musculoskeletal Involvement in cGVHD: It could be employed in patients with resistant skin changes, including scleroderma (a chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues) like features and contractures of joints that have not responded to other interventions.

• Progressive Pulmonary cGVHD: Axatilimab has applications in addressing lung manifestations in cGVHD, which may manifest as bronchiolitis obliterans syndrome, a proliferative and irreversible disease resulting in airway fibrosis and obstruction.

What Are the Contraindications of Axatilimab-csfr?

• Active Infections: Due to its immunomodulatory effects, Axatilimab can only be used in patients with well-controlled infections because the drug may worsen the infection’s course.

• Pre-existing Pulmonary Fibrosis (Unrelated to cGVHD): As macrophages are vital for tissue remodeling, patients with pre-existing severe lung fibrosis may experience health deterioration.

• Severe Cardiovascular Disease: For this reason, Axatilimab is specifically not recommended for use in patients with severe, poorly compensated cardiovascular diseases owing to the possibility of changes in hemodynamics and immunomodulatory effects.

• Hypersensitivity to Axatilimab or Its Components: Patients who are hypersensitive or allergic to one or more components of the formulation should avoid taking this medication.

Available Doses and Dosage Forms:

Axatilimab-csfr is available as an injectable solution:

Doses:

• 50 mg/mL (Milligrams per Milliliter) Solution for Injection: Commonly used for initial and maintenance dosing.

• 100 mg/mL Solution for Injection: Used for patients requiring a higher dose or in cases of severe, refractory disease.

Normal Dosage Schedule:

• Induction Dose: Outpatients received doses of three mg/kg (milligrams per kilogram) every two weeks for the first twelve weeks of the study.

• Maintenance Dose: Three mg/kg every four weeks or 0.6 mg/kg every two weeks, depending on clinical response and tolerability of the side effects.

The dosages may vary based on the patient's response, the drug's side effects, or using weight change as a pointer.

For Patients:

How Does Axatilimab-csfr Work in Chronic Graft-Versus-Host Disease?

Axatilimab-csfr is a novel therapy for cGVHD, which works on colony-stimulating factor 1 receptor (CSF-1R). This monoclonal antibody targets CSF-1R and blocks its activating by its ligands; CSF-1 and IL-34. By antagonizing CSF-1R, it suppresses inflammation, and consequently, the trajectories of monocyte and macrophage recruitment, proliferation, differentiation, and survival that underlie cGVHD. This kind of treatment brings hope to patients who otherwise have few treatment choices and improves the management of the disease.

What Special Precautions Should Be Taken?

Those on Axatilimab should be closely monitored for instances of infection because the medicine affects the immune system. They should also not take live vaccines because attenuated pathogen activation is possible. Patients should have follow-up blood tests at regular intervals during that period, for instance, liver function tests, complete blood counts, and kidney function tests to check on their safety while on treatment. Patients should be advised to report any new signs and symptoms or worsening of existing symptoms, especially those of respiratory origin, since Axatilimab affects lung capacity.

What Are the Side Effects of Axatilimab-csfr?

The side effects are generally mild and are thought to be related to infusion reactions: fever, chill, and fatigue, which usually start during the first few hours after infusion. Some indications include transient elevations of liver enzymes, which calls for dose adjustments. Of these serious but rare side effects are lung toxicity, increased risk of infections, and effects on the cardiovascular system such as arrhythmias ( abnormal heart rhythms where the heart beats too fast, too slow, or irregularly). Any reactions should be discouraged and reported to the healthcare providers as soon as possible to avoid other occurrences.

Storage of Axatilimab-csfr:

Axatilimab-csfr must be refrigerated at two to eight degrees Celsius (36 to 46 degrees Fahrenheit). It should not be frozen or exposed to light since the ingredients reduce its ability upon exposure to light. It is almost impossible to describe the principles of storing the vial together with its original packaging; it is necessary to mention that the packaging material also possesses the ability to protect the vial from light. When applied, it should be used for 24 hours if stored at room temperature and 72 hours if stored in the refrigerator. The remainder should be disposed of according to laws controlling biological waste if some remain unused.

For Doctors:

Pharmacodynamics:

Axatilimab-csfr develops the pharmacodynamics activity by interacting with CSF1R, a macrophage receptor with significant relevance to the signaling pathways. Through the blockage of CSF1R, Axatilimab decreases macrophage differentiation and proliferation and downgrades their secretion of inflammatory and fibrotic cytokines. This mechanism is useful in managing cGVHD with excessive macrophage-influenced chronic inflammation and fibrosis in many organs. The affected patients ' organ dysfunction and clinical manifestations are alleviated due to Axatilimab’s impact on macrophages and decreased tissue lesions.

Pharmacokinetics:

Absorption:

• Intravenous Administration: Axatilimab is an intravenous drug, which means that it attains systemic exposure very fast.

• Bioavailability: Proposed to have nearly 100 percent bioavailability because it bypasses the first-pass metabolism after IV infusion.

Distribution:

• Plasma Protein Binding: High plasma protein binding of Axatilimab to albumin affects its pharmacokinetics.

• Volume of Distribution: It has a low volume of distribution, indicating limited extravascular distribution.

Metabolism: Axatilimab is mainly eliminated via protein degradation mechanisms, typical for other monoclonal antibodies. The liver barely metabolizes it.

Excretion:

• Half-Life: Based on its biweekly to monthly administration, the terminal half-life is about 12 to 15 days.

• Renal and Hepatic Excretion: Axatilimab is primarily cleared via reticuloendothelial and renal systems, necessitating monitoring in patients with significant renal or hepatic impairment.

Toxicity:

Symptoms of an overdose of Axatilimab-csfr are a life-threatening immunosuppressive state and heightened susceptibility to infections. It may cause pulmonary toxicity in patients as well as cardiovascular instability. Possible toxic effects include abrupt development of fever, severe reactions to the infusion, or new manifestations of respiratory problems. Management should be symptomatic; the patient should be closely observed; dose reduction or withdrawal may be indicated in individual cases according to the severity of the reaction.

What Are the Drug Interactions?

• Immunosuppressive Agents: Axatilimab, when used together with other immunosuppressive agents such as calcineurin inhibitors and Mycophenolate mofetil, carries a high risk of severe immunosuppression. This may result in increased infections, poor wound healing, or blood-related problems, so depending on the immune position, it is recommended to check the complete blood count frequently.

• Corticosteroids: Axatilimab and corticosteroids may increase the likelihood of secondary infections, hyperglycemia, and other side effects of corticosteroids. Blood glucose and infection activities must be closely checked, and a healthcare provider may advise a slight decrease in cortisone doses.

• Antifibrotic Agents: Patients receiving Axatilimab should exercise some degree of precaution when receiving antifibrotic drugs such as Pirfenidone and Nintedanib because these drugs may have similar side effects on the liver. A liver function test is recommended at the beginning of the treatment and periodically to identify hepatic toxicity and decide the dosage.

• Biologic Agents: Combining with other biologics like Rituximab or Infliximab may enhance immunosuppression and increase susceptibility to infections or the reoccurrence of dormant infections. It is safe to use this combination when the benefits outweigh the risks, and signs of infection must be monitored.

• Live Vaccines: Do not use live vaccines such as MMR (Measles, Mumps, and Rubella) or varicella with Axatilimab, and acute infections may occur due to immunosuppression. Thus, it is recommended to use inactivated or non-live vaccines preferentially; however, the timing of their administration should not be done simultaneously with Axatilimab therapy.

• Cytochrome P450 (CYP) Inhibitors of Inducers: The metabolic pathway study showed that CYP enzymes do not extensively metabolize Axatilimab, but strong inhibitors or inducers can still affect the clearance of the compound. Some patients may require dose adjustments depending on efficacy and any side effects it may produce.

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Concomitant use of NSAIDs, including Ibuprofen and Naproxen, with Axatilimab, increases susceptibility to gastrointestinal bleeding or renal dysfunction. Special attention should be paid to possible signs manifested as gastrointestinal discomfort, changes in renal function, or changes in blood.

• Digoxin: Hypersensitivity to cardiovascular effects of Digoxin may manifest in nausea, changes in vision, and arrhythmia that Axatilimab might cause. Closely follow Digoxin concentrations and provide necessary modifications to both the dosage and the type of Digoxin to avoid toxicity.

• Antihypertensive Drugs: If the body produces proteins that lessen blood coagulation platelet creation, Axatilimab may impact blood pressure regulation and influence hypertensives like beta blockers or ACE (Angiotensin-Converting Enzyme)inhibitors. Check blood pressure occasionally and dose the antihypertensive medications where necessary.

• Monoamine Oxidase Inhibitors (MAOIs): Coadministration of Axatilimab with MAOI drugs such as Phenelzine will increase the risk of developing a hypertensive crisis due to its interaction with sympathetic pathways. This combination should be avoided; instead, other modes of treatment should be sought.

Use In Special Populations:

• Pregnancy Considerations: Since Axatilimab is not safe for pregnant women, it may affect fetal development, for example, leading to immune dysfunction or organ deformity. Oil of oregano overlaid with documented arbitrary patterns should be utilized only after prudent appraisal of benefit-risk ratios and other therapeutic options, with contraception recommended during and for six months after treatment.

• Breastfeeding Concerns: It is not known how this medication is removed from the body through breast milk, but breastfeeding may be unsafe since Axatilimab affects the immune system. A woman still nursing her child should seek medical advice on the risks. Depending on the severity, medical advice may advise on other forms of treatment or complete abstaining from breastfeeding.

• Pediatric Patients: However, Axatilimab is not authorized for use in children under 18, and its short-term use in pediatric patients with cGVHD is not recommended. Others should, therefore, be considered first, with Axatilimab only used when the overall benefits are likely to outweigh the side effects under controlled medical conditions.

• Geriatric Patients: Patients with renal disease may receive less Axatilimab, reducing efficacy and increasing immunosuppressive effects. This can also lead to liver disease, which is also dangerous for geriatric patients. Reduced doses of Axatilimab, with particular attention paid to hepato-renal function and immune status, are advised to avoid adverse effects.